Estraval Depot: Estradiol Uses, Benefits, and Safety
Written by Elizabeth Chernoby in TheSkyMeds Editorial Standards
Medically reviewed by Jonathan Reed, Medical Content Reviewer Sept 23 2026
Estraval Depot is a prescription estrogen injection containing estradiol valerate, a long-acting ester that is converted to estradiol in the body. Current manufacturer information identifies Estraval Depot as a 10 mg estradiol valerate ampoule intended for intramuscular administration and hormone therapy. Estraval Depot may be prescribed when estrogen replacement is medically appropriate, including selected situations involving estrogen deficiency and menopausal symptoms. Estrogen therapy is highly effective for hot flashes and night sweats and can prevent menopause-related bone loss, but its benefits and risks depend on age, medical history, treatment timing, route, dose, and whether the patient still has a uterus. In people with a uterus, systemic estrogen generally requires appropriate progestogen protection to reduce the risk of endometrial cancer. Because injectable estrogen is systemic and long-acting, Estraval Depot should be prescribed and monitored rather than used as a general anti-aging or wellness hormone.
What Is Estraval Depot and What Is It Used For?
Estraval Depot is an injectable form of estradiol valerate. Manufacturer information identifies a 10 mg ampoule and describes the product as hormone replacement therapy for conditions related to estrogen deficiency.
Estradiol valerate is an ester of estradiol. After administration, it is converted into active estradiol, which binds to estrogen receptors and produces estrogenic effects throughout the body.
The Estraval Depot manufacturer product information identifies the active ingredient as estradiol valerate, the dosage form as an ampoule, and the product strength as 10 mg.
What conditions can estrogen therapy treat?
Systemic estrogen has established uses in managing symptoms associated with estrogen deficiency. During menopause, declining estrogen can contribute to hot flashes, night sweats, sleep disruption, and genitourinary symptoms such as vaginal dryness.
Estrogen replacement is also used in selected younger patients with inadequate estrogen production. For example, ACOG recommends estrogen replacement in primary ovarian insufficiency, with appropriate progestogen protection when the uterus is present.
Estradiol can additionally be used in gender-affirming hormone therapy. The precise indication, dose, route, and monitoring requirements differ substantially from menopausal hormone therapy and should be determined by a clinician experienced in that area.
Estraval Depot replaces or supplies estrogen; it is not a general “hormone-balancing” injection for anyone with tiredness, mood changes, or aging-related symptoms. The reason for estrogen therapy should be established first because its expected benefits and safety profile depend heavily on the indication and the individual.
What Benefits Can Estraval Depot Provide?
The clearest benefits of systemic estrogen are relief of troublesome menopausal vasomotor symptoms and prevention of bone loss in appropriate patients. Hormone therapy can also improve estrogen-related genitourinary symptoms, although local vaginal estrogen may be preferable when vaginal symptoms are the only concern.
Hot flashes and night sweats
Systemic estrogen is the most effective treatment for menopausal hot flashes and night sweats. Both ACOG and The Menopause Society identify hormone therapy as highly effective for these vasomotor symptoms.
The ACOG guidance on hormone therapy for menopause also emphasizes individualized selection according to symptoms and personal and family medical history.
Vaginal and urinary symptoms of menopause
Estrogen therapy can improve vaginal dryness associated with menopause. However, systemic treatment is not automatically necessary when symptoms are confined to vaginal or genitourinary tissues.
The Menopause Society recommends low-dose vaginal estrogen or other targeted therapies for bothersome genitourinary syndrome of menopause when there is no separate indication for systemic hormone therapy.
Bone health
Systemic estrogen prevents bone loss associated with menopause and can reduce fracture risk.
This does not mean Estraval Depot is automatically the preferred osteoporosis medicine for every postmenopausal person. Bone-fracture risk, menopausal symptoms, age, contraindications, and alternative osteoporosis treatments all influence the decision.
Estradiol benefits and how strong the evidence is
Potential benefit | Evidence perspective |
Reduce menopausal hot flashes | Well established |
Reduce night sweats | Well established |
Improve estrogen-related vaginal dryness | Established |
Prevent menopause-related bone loss | Established |
Reduce fracture risk during appropriate systemic hormone therapy | Supported |
Treat estrogen deficiency in selected patients | Established medical use |
Improve general “hormonal balance” without a diagnosed indication | Not an evidence-based indication |
Prevent cardiovascular disease | Should not be used for this purpose alone |
Reverse normal aging | Not established |
Guarantee better skin, hair, mood, or energy | Not established as a predictable treatment outcome |
Hormone therapy should therefore be judged against a specific clinical goal rather than a broad promise of rejuvenation.
Who Needs Progesterone With Estradiol?
People who still have a uterus generally require appropriate endometrial protection when systemic estrogen is used. Estrogen stimulates the uterine lining, and prolonged estrogen exposure without sufficient progestogen can increase the risk of endometrial hyperplasia and endometrial cancer.
ACOG explains that people who have not had a hysterectomy generally need a progestin alongside systemic estrogen. If the uterus has been removed, estrogen-only therapy may be appropriate.
Why does the uterus matter?
The endometrium—the lining inside the uterus—responds to estrogen by growing. Progesterone or a progestin counteracts this stimulation and helps protect the endometrium.
That is why systemic estrogen should not be considered in isolation when a uterus is present. The appropriate progestogen regimen depends on the hormone-therapy plan and should be prescribed by the treating clinician.
Is progesterone needed after hysterectomy?
Usually, estrogen can be given without a progestogen after the uterus has been removed, although individual circumstances can alter treatment decisions.
A patient's surgical history therefore matters before starting Estraval Depot or another systemic estrogen product.
What Are the Risks and Side Effects of Estradiol Therapy?
Systemic estrogen therapy has both common adverse effects and less common but potentially serious risks. Risk is not identical for every person; it varies with age, underlying health, treatment timing, estrogen formulation, dose, route, duration, and use of a progestogen.
Common hormone-therapy adverse effects can include breast tenderness, nausea, irregular bleeding or spotting, bloating, and headaches. An injection can also cause local discomfort or injection-site reactions.
Estradiol safety issues to recognize
Issue | What to know |
Breast tenderness | Can occur during hormone therapy |
Headache or nausea | Recognized adverse effects |
Spotting or vaginal bleeding | Can occur, but unexpected or persistent bleeding needs assessment |
Fluid retention/bloating | Possible during treatment |
Blood clot | Systemic hormone therapy can increase risk |
Stroke | Risk can increase with systemic hormone therapy |
Endometrial cancer | Risk rises when systemic estrogen is used without adequate progestogen in someone with a uterus |
Breast cancer | Risk varies with hormone regimen and duration; combined therapy carries different risk from estrogen alone |
Gallbladder disease | Estrogen therapy can increase risk |
Pregnancy | Systemic menopausal hormone therapy is not used during pregnancy |
ACOG notes that both estrogen-only and combined systemic hormone therapy are associated with a small risk of stroke and deep-vein thrombosis, with risk influenced by age and other factors.
Does estrogen cause breast cancer?
The answer depends on the hormone regimen and duration rather than simply whether estrogen is present.
ACOG states that combined estrogen-progestin therapy is associated with a small increased risk of breast cancer. Estrogen-only therapy has a different risk profile, which is one reason hormone-therapy counseling must account for whether the uterus is present and which regimen is being considered.
A personal history of hormone-sensitive breast cancer substantially changes the decision, and nonhormonal approaches are generally considered first for menopausal symptoms.
What about blood clots and stroke?
Systemic hormone therapy can increase the risk of venous thromboembolism—blood clots such as deep-vein thrombosis—and stroke.
Importantly, risk varies by route. Evidence reviewed by ACOG suggests oral estrogen has a stronger prothrombotic effect, while transdermal estrogen may have less effect on clot-promoting markers. This should not be used to assume that a depot injection has the same risk profile as a patch; route-specific decisions require appropriate clinical evidence.
Who Should Avoid or Use Estraval Depot With Extra Caution?
Systemic estrogen is not suitable for everyone. A personal medical and family history should be reviewed before treatment, particularly for cancer, blood clots, cardiovascular disease, liver disease, and unexplained vaginal bleeding.
ACOG states that systemic hormone therapy is usually not recommended in people with a history of breast or endometrial cancer, stroke, heart attack, blood clots, or liver disease. It should not be used during pregnancy.
The Menopause Society guidance on hormone therapy benefits and risks similarly stresses individualized assessment and notes that breast or uterine cancer, unexplained uterine bleeding, liver disease, previous blood clots, and cardiovascular disease can make hormone therapy inappropriate.
Does age affect hormone-therapy safety?
Yes. Age and the time elapsed since menopause influence the balance between benefit and risk.
The Menopause Society's 2022 position statement concluded that, in women younger than 60 or within 10 years of menopause onset who have no contraindications, the benefit-risk balance is generally favorable for bothersome vasomotor symptoms and prevention of bone loss.
Starting systemic hormone therapy more than 10 years after menopause or after age 60 generally produces a less favorable benefit-risk balance because the absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia are higher.
This is a population-level principle, not an automatic age cutoff for every individual.
How Is Estraval Depot Given and Monitored?
Estraval Depot is an intramuscular depot injection and should be used according to a clinician-prescribed regimen. Manufacturer information identifies the product as an injectable estradiol valerate formulation and states that administration should occur under healthcare supervision.
There is no single injection interval that should be recommended to every reader. Dose and frequency can differ according to the indication, response, other hormones used, medical history, and specific formulation.
What should be checked before treatment?
A clinical assessment should establish why estrogen is being prescribed and whether contraindications or important risk factors are present. Relevant considerations can include uterine status, unexplained bleeding, pregnancy possibility, breast and endometrial cancer history, clotting history, cardiovascular disease, liver disease, and other medications.
For menopausal therapy, ACOG recommends ongoing discussion about whether treatment should continue, based on symptoms, benefits, and changing risks.
How long can estrogen therapy continue?
There is no universally correct duration for every patient. Treatment should continue only while its indication and individual benefit-risk balance justify it.
The Menopause Society notes that some people need longer treatment for persistent symptoms and recommends periodic reevaluation rather than an automatic stopping point.
This is particularly important with long-acting injected estrogen because the administered dose cannot simply be removed after injection if an adverse effect occurs.
When Should You Seek Medical Attention?
Contact your healthcare professional about new or persistent abnormal vaginal bleeding, a breast lump, troublesome headaches, significant swelling, jaundice, or other new symptoms while receiving systemic estrogen.
Seek urgent medical care for symptoms that could indicate a blood clot, stroke, or other serious event. These include sudden chest pain or breathlessness, coughing up blood, painful swelling in one leg, sudden weakness or numbness—especially on one side—difficulty speaking, sudden severe headache, or sudden significant visual disturbance.
Unexplained vaginal bleeding before starting systemic estrogen also requires assessment rather than simply treating presumed menopause symptoms. The Menopause Society lists unexplained uterine bleeding among circumstances in which systemic hormone therapy generally should not be used.
Hormone treatment should also be reviewed if pregnancy occurs or is suspected. ACOG states that menopausal hormone therapy is not intended for pregnant patients.
Conclusion
Estraval Depot is a long-acting estradiol valerate injection used when systemic estrogen therapy is medically appropriate. Estradiol can provide substantial benefits for estrogen-deficiency symptoms, particularly menopausal hot flashes and night sweats, and systemic estrogen can prevent menopause-related bone loss. However, it is not a general anti-aging or wellness injection.
Safety depends on the indication, age, cardiovascular and clotting history, cancer history, uterine status, treatment route, and other medicines. Anyone with a uterus usually requires appropriate progestogen protection during systemic estrogen therapy. Estraval Depot should therefore be prescribed, administered, and periodically reviewed by a clinician rather than self-dosed or used according to a generic injection schedule.
Frequently Asked Questions
1. What is Estraval Depot used for?
Estraval Depot contains estradiol valerate and is used for systemic estrogen therapy when estrogen replacement is clinically appropriate. Estrogen therapy has established roles in relieving menopausal hot flashes and night sweats and managing selected estrogen-deficiency conditions. The precise indication should be determined medically.
2. Is Estraval Depot the same as estradiol?
Estraval Depot contains estradiol valerate, an ester that is converted to active estradiol in the body. Estradiol then acts through estrogen receptors. The depot formulation is designed for sustained release after intramuscular injection rather than immediate short-duration exposure.
3. Does Estraval Depot help with menopause symptoms?
Systemic estrogen is the most effective treatment for menopausal hot flashes and night sweats and can also improve estrogen-related vaginal dryness. Whether an injectable formulation is appropriate depends on individual risks, symptoms, treatment goals, and available alternatives.
4. Do I need progesterone with Estraval Depot?
If you still have a uterus, systemic estrogen generally requires an appropriate progestogen to protect the uterine lining. Estrogen without adequate protection can increase endometrial hyperplasia and cancer risk. People who have had a hysterectomy usually have different hormone-therapy requirements.
5. Can Estraval Depot cause blood clots?
Systemic estrogen therapy can increase the risk of venous blood clots and stroke, although absolute risk varies with age, health, formulation, and route. Previous blood clots are therefore an important part of the medical history reviewed before systemic hormone therapy.
6. Is Estraval Depot safe for long-term use?
There is no single safe duration that applies to everyone. Hormone therapy should be individualized and periodically reassessed according to continuing symptoms, age, medical history, treatment type, and evolving risks. Longer treatment can be appropriate for documented indications after individualized benefit-risk review.
Comments